Valiant Laboratories Ratios

Valiant Laboratories Ltd Ratios

The Valiant Laboratories Ltd Ratios page provides a complete fundamental analysis of Valiant Laboratories Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Valiant Laboratories Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Valiant Laboratories Ltd (NSE: VALIANTLAB, BSE: 543998) is currently trading at ₹57.28, with a market capitalization of ₹3.09B. As a major player in the Health technology sector and Pharmaceuticals: major industry, Valiant Laboratories Ltd remains a key stock for fundamental analysis using Valiant Laboratories Ltd Ratios.

Valiant Laboratories Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Valiant Laboratories Ltd P/E ratio currently stands at 0, making it one of the most tracked metrics in Valiant Laboratories Ltd Ratios.

Historically, the Valiant Laboratories Ltd P/E ratio has shown strong fluctuations:

• 2024: 0
• 2023: 1730
• 2022: 0
• 2021: 0
• 2020: 0

The decline in Valiant Laboratories Ltd P/E ratio suggests improving earnings relative to stock price.

Price to Book Ratio (P/B)

The Valiant Laboratories Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 1.42.

Historical P/B trend:

• 2024: 1.42
• 2023: 2.67
• 2022: 0
• 2021: 0

Valiant Laboratories Ltd shows reasonable valuation compared to its asset base.

Price to Sales Ratio (P/S)

The Valiant Laboratories Ltd P/S ratio currently stands at 2.50, an important part of Valiant Laboratories Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 2.50
• 2023: 3.04
• 2022: 0
• 2021: 0

A stable or declining Valiant Laboratories Ltd P/S ratio indicates cautious market sentiment.

Valiant Laboratories Ltd Price to Cash Flow Ratio (P/CF)

The Valiant Laboratories Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 254.

Historical Valiant Laboratories Ltd Price to Cash Flow Ratio:

• 2024: 254
• 2023: 306.13
• 2022: 0
• 2021: 0
• 2020: 0

The declining Valiant Laboratories Ltd Price to Cash Flow Ratio suggests improving cash flow strength.

Valiant Laboratories Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Valiant Laboratories Ltd EV currently stands at ₹3.79B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 3.79B
• 2023: 4.86B
• 2022: 0
• 2021: 0

Valiant Laboratories Ltd enterprise value consolidation suggests stable valuation.

EV/EBITDA Ratio

The Valiant Laboratories Ltd EV/EBITDA ratio is currently 0, a key metric in Valiant Laboratories Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 0
• 2023: 0
• 2022: 0
• 2021: 0

Stable Valiant Laboratories Ltd EV/EBITDA indicates balanced valuation.

Valiant Laboratories Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Valiant Laboratories Ltd D/E ratio is currently 0.52, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.52
• 2023: 0.32
• 2022: 0.60
• 2021: 0.86

Valiant Laboratories Ltd maintains moderate leverage with manageable risk.

Return on Equity (ROE %)

The Valiant Laboratories Ltd ROE currently stands at -0.93%, showing profitability and capital efficiency.

Historical ROE:

• 2024: -0.93
• 2023: 0.19
• 2022: 33.73
• 2021: 34.36

Declining ROE indicates pressure on profitability.

Valiant Laboratories Ltd Ratios Analysis Summary

The Valiant Laboratories Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Valiant Laboratories Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Valiant Laboratories Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.